Analysts Set Expectations for Zai Lab FY2025 Earnings

Zai Lab Limited (NASDAQ:ZLAB) – Investment analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Zai Lab in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst L. Chen expects that the company will post earnings of ($1.38) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Zai Lab’s current full-year earnings is ($2.58) per share.

Separately, JPMorgan Chase & Co. raised their price objective on Zai Lab from $38.00 to $44.00 and gave the stock an “overweight” rating in a research note on Monday, October 21st.

Zai Lab Stock Down 0.2 %

Shares of Zai Lab stock opened at $26.00 on Wednesday. The stock’s fifty day moving average is $26.71 and its 200 day moving average is $23.68. Zai Lab has a one year low of $13.48 and a one year high of $36.60.

Institutional Investors Weigh In On Zai Lab

A number of institutional investors have recently added to or reduced their stakes in ZLAB. Janus Henderson Group PLC grew its stake in Zai Lab by 34.2% during the third quarter. Janus Henderson Group PLC now owns 8,760,074 shares of the company’s stock valued at $211,488,000 after acquiring an additional 2,232,507 shares in the last quarter. Wellington Management Group LLP lifted its position in Zai Lab by 18.4% in the third quarter. Wellington Management Group LLP now owns 8,436,606 shares of the company’s stock worth $203,660,000 after buying an additional 1,312,115 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its stake in shares of Zai Lab by 26.2% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 604,153 shares of the company’s stock worth $14,584,000 after purchasing an additional 125,532 shares during the period. Bamco Inc. NY boosted its position in shares of Zai Lab by 6.4% during the third quarter. Bamco Inc. NY now owns 1,906,520 shares of the company’s stock valued at $46,023,000 after buying an additional 113,869 shares during the period. Finally, Algert Global LLC bought a new position in Zai Lab in the 3rd quarter valued at $1,666,000. 41.65% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, insider Rafael Amado sold 7,583 shares of the stock in a transaction dated Tuesday, December 31st. The stock was sold at an average price of $26.28, for a total transaction of $199,281.24. Following the completion of the sale, the insider now owns 33,834 shares in the company, valued at approximately $889,157.52. This trade represents a 18.31 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 13.88% of the company’s stock.

About Zai Lab

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.